Pharmafile Logo

What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?

December 23, 2025 |  

Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We discussed their involvement in the recently formed RDI-Lancet Commission for Rare Diseases, a global initiative aimed at developing evidence-based recommendations to improve the lives of the 400 million people living with rare diseases worldwide.

lucy                           Picture1megan

Lucy McKay                                                  Megan Pullein
CEO                                                                Strategic Operations Officer
Medics for Rare Disease                            Medics for Rare Disease

Christy: It’s lovely to be speaking with one of our favourite partners in rare disease, Medics for Rare Disease! Lucy, and Megan, could you start by introducing yourselves, Medics for Rare Disease, and its mission?

Lucy: Absolutely, I’m Dr Lucy McKay, the CEO of Medics for Rare Disease, and our vision is simple: equitable healthcare for everyone. Our mission is to shape a medical profession that can provide timely diagnosis and excellent care to people living with rare diseases.

Megan: I’m Megan Pullein, and I’m the Strategic Operations Officer at Medics for Rare Disease. My primary role is to help manage our work with the RDI-Lancet Commission, specifically for Working Group 2, which Lucy Co-Chairs.

Christy: What are the Lancet Commissions, and what is the RDI-Lancet Commission for Rare Diseases?

Megan: The Lancet Commissions are in-depth research initiatives that tackle urgent and complex global health issues. They gather experts from around the world to collaborate on solutions, which are then published in the renowned medical journal. The vision for this specific commission is to make rare diseases visible globally, ensuring that every person is seen, heard, and cared for, no matter where they live. The goal is to produce actionable recommendations that any government can take and implement within their society.

Christy: I understand that the commission is divided into 5 working groups. What is the focus of each?

Lucy: Before breaking down the groups, it’s important to state the golden thread that runs through all of this: human rights. The entire commission is fundamentally about achieving equity for patients around the world.

Megan: That leads perfectly into Working Group 1, which is focused on visibility for human rights. This is the core of the commission. Working Group 2, which we are leading, focuses on visibility for social justice. These are the 2 overarching themes. The other groups are more specific: Group 3 is looking at data and metrics; Group 4 is tackling visibility within healthcare systems, particularly the diagnostic odyssey; and Group 5 is focused on clinical pathways and trials.

Christy: Where does the work for each group start, and where does it end?

Lucy: We’re working in 3 phases. For example, in Working Group 2, first is a comprehensive literature review to answer the question: is social justice being achieved for people living with rare disease? If so, how? And if not, why not?

The second phase is generating new evidence. We want to fill the gaps we find in the literature, especially from geographical and demographical sources that are currently missing. We have a lofty goal of trying to represent advocates from every UN-recognized country, starting with the places from which we hear no voices.

The final phase will be to consolidate this evidence into concrete recommendations.

Christy: What do you find most exciting about RDI-Lancet Commission?

Lucy: For The Lancet to even highlight Rare Disease is a major milestone in history. What excites me is that this project forces us to pull back to focus on the individual. We constantly have to ask, for example, How is this recommendation going to help someone in rural Chile? It moves the conversation beyond tech, molecules, and industry chatter. Tech doesn’t matter to people if they can’t access it or are being treated without the respect every human being deserves.

It allows us to establish a global standard of provision for the rare disease community and will help shape The World Health Organisation’s Global Action Plan for Rare Disease. We hope that in the future there will be greater standardisation and transparency in how nations care for rare diseases. This will empower the rare disease community to understand what they are entitled to, the barriers to access and to demand accountability.

Christy: Thank you so much Lucy and Megan, it’s exciting to see this research moving forward, and we’re all looking forward to seeing the forthcoming publications.

For more information on the RDI-Lancet Commission:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00211-9/abstract

About Medscape Education

Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional

This content was provided by Medscape Education

Company Details

 Latest Content from  Medscape Education 

Medscape Education Global to Join Biotechs at Swiss Biotech Day

The Medscape Education Global team is excited to announce its participation in Swiss Biotech Day, taking place in Basel from May 5-6. This marks our inaugural attendance at this event,...

Gut Check: A Game-Changing Experience at DDW 2025 with Medscape!

The countdown is on! The Medscape team is heading to San Diego for this year’s highly anticipated Digestive Disease Week (DDW) conference—and you won’t want to miss what we’ve got...

Looking Ahead: Transparency, Impact, and Instructional Design at CMEpalooza Spring 2025

Tomorrow at 2 PM ET, join Medscape for a thought-provoking Afternoon Snack Session at CMEpalooza Spring 2025, titled “Reverse Planning with Forward Thinking.” This session will spotlight how clear communication...

Vaccines Are the Most Impactful Innovation in Health Equity

As deadly as the measles outbreak in west Texas and New Mexico is the spread of vaccine conspiracy theories and misinformation. According to KFF research from November 2024, childhood vaccination...

Collaboration Across Healthcare is the Path Forward

How do we impress upon women that they need to prioritize their own health before providing for the people who need them? A leader in medical oncology has a few...

Medscape at ESCMID 2025: Advancing Infectious Disease Education

Medscape, a global leader in infectious disease education, continues its commitment to advancing knowledge in the field. With 1.47 million ID learners in 2024, the Medscape team will travel to...

The future of heart health with AI-powered devices and treatment approaches

Artificial intelligence (AI) is revolutionising the field of cardiology, offering new hope for patients with cardiovascular disorders. AI is no longer futuristic, it’s a real-world tool, transforming patient care and...

Medscape at ACC 2025: From Taking the Pulse to Getting to the Heart of It

The Medscape team is back in Chicago for the much-anticipated ACC 2025 conference,  March 29-31, bringing an array of engaging educational booth highlights, interactive symposia, scientific posters, and more for...

Michelle Worst Honored With 2025 HOPA Volunteer Award

Medscape is proud to highlight Michelle A. Worst, PharmD, BCOP, MBA, CHCP, Senior Director and Team Lead of Clinical Strategy in Hematology/Oncology, for her well-deserved recognition as the recipient of...

Innovations in Women’s Health Coalition Launches New Global Efforts

Medscape Education, the leader in continuing medical education for healthcare professionals, is extending its commitment to closing gaps in women's health by expanding the efforts of its Innovations in Women's...